Pharma BD Deal Intelligence

Bayer AG / Schering AG

2006 · Acquisition/Merger · $21.5B · Complete

Bayer acquired Schering AG for approximately EUR 17 billion (~$21.5 billion) in an all-cash tender offer, outbidding rival Merck KGaA to gain Schering's strong portfolio in women's health (Yasmin), diagnostic imaging (Magnevist), and oncology pipeline including Nexavar.

Key facts

• Announced Mar 23, 2006
• Closed Dec 29, 2006
• Deal value $21.5B
• Deal type Acquisition/Merger
• Therapeutic area Dermatology, Hematology, Neurology, Oncology, Women's Health
• Indications Contraception, Multiple sclerosis, MRI contrast imaging, Renal cell carcinoma, Hepatocellular carcinoma
• Key assets Yasmin/YAZ (drospirenone/ethinyl estradiol), Betaferon (interferon beta-1b), Magnevist (gadopentetate dimeglumine), Nexavar (sorafenib, co-developed with Onyx), Mirena (levonorgestrel IUD), Ultravist (iopromide), Schering Berlin diagnostic imaging portfolio
• Mechanism Progestin/estrogen combination, Interferon beta immunomodulator, Gadolinium-based MRI contrast agent, Multi-kinase inhibitor (VEGFR/PDGFR/RAF)

← Browse all deals  ·  How we score deals